Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples.
We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease.
The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001).
The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings.
Anticancer research. 2018 Mar [Epub]
Jinan Guo, Jianggen Yang, Xuhui Zhang, Xiaoyan Feng, Heqiu Zhang, Lingwu Chen, Heather Johnson, Jenny L Persson, Kefeng Xiao
Department of Urology, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen Urology Minimally Invasive Engineering Center, Shenzhen, P.R. China., Department of Bio-diagnosis, Institute of Basic Medical Sciences, Beijing, P.R. China., Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, P.R. China., Olympia Diagnostics, Inc., Sunnyvale, CA, U.S.A., Department of Translational Medicine, Lund University, Malmö, Sweden ., Department of Urology, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), Shenzhen Urology Minimally Invasive Engineering Center, Shenzhen, P.R. China .